Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro ...
Oruka Therapeutics files to sell 8.72M shares of common stock for holders
EST Oruka Therapeutics (ORKA) files to sell 8.72M shares of common stock for holders Published first on TheFly – the ultimate ...
Wedbush Reaffirms Their Buy Rating on Oruka Therapeutics (ORKA)
Wedbush analyst David Nierengarten maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today and set a price target of ...
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical ...
Oruka Therapeutics (ORKA) versus The Competition Critical Contrast
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka ...
Contrasting Oruka Therapeutics (ORKA) & The Competition
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its peers? We will compare Oruka ...